Investors

We identify critical gaps in care across serious psychiatric and neurologic conditions and develop differentiated medicines with a focus on novel mechanisms of action. Our industry-leading CNS portfolio spans multiple FDA-approved medicines and a deep pipeline addressing unmet needs across a broad range of conditions, including Alzheimer’s disease agitation, major depressive disorder, narcolepsy, attention-deficit/hyperactivity disorder, schizophrenia, and more.